- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn | 4 | GlobeNewswire (USA) | ||
| Di | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.12. | Pelthos Therapeutics signs first commercial deal for molluscum treatment | 3 | Investing.com | ||
| 04.12. | Pelthos Therapeutics sichert sich ersten Vertriebsvertrag für Molluscum-Medikament | 1 | Investing.com Deutsch | ||
| 04.12. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI (berdazimer) Topical Gel, 10.3% | 129 | GlobeNewswire (Europe) | ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new... ► Artikel lesen | |
| 25.11. | Pelthos Therapeutics stock initiated with Buy rating at Roth/MKM | 3 | Investing.com | ||
| 13.11. | Pelthos Therapeutics GAAP EPS of -$5.30 | 1 | Seeking Alpha | ||
| 13.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results | 124 | GlobeNewswire (Europe) | Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1... ► Artikel lesen | |
| 13.11. | Pelthos Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer | 13 | Pharmaceutical Technology | ||
| 07.11. | Pelthos Acquires US Rights To Xepi, Secures $18 Mln Financing | - | RTTNews | ||
| 07.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing | 285 | GlobeNewswire (Europe) | Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMIXepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in... ► Artikel lesen | |
| 07.11. | Biofrontera Inc. announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M | 181 | GlobeNewswire (Europe) | Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further... ► Artikel lesen | |
| 07.11. | EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch | 2 | Benzinga.com | ||
| 07.11. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 | 1 | GlobeNewswire (USA) | ||
| 14.10. | Pelthos Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.10. | Pelthos rolls out Zelsuvmi with campaign aimed at moms who 'don't mess around' | 3 | FiercePharma | ||
| 09.10. | Pelthos launches Moms Against Molluscum campaign for skin infection | 1 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,388 | +3,10 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| VALNEVA | 3,654 | -1,77 % | Morgen-Update: Valneva-Aktie explodiert - Anleger im Kaufrausch! | ||
| MAINZ BIOMED | 1,270 | +8,55 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| AMGEN | 332,93 | -0,31 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| INSMED | 177,88 | +0,26 % | INSMED INC kurz vor dem Durchbruch - ich greife jetzt zu! | ||
| ROIVANT SCIENCES | 22,230 | -1,20 % | Roivant Sciences: Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day | Roivant enters new phase of corporate journey with 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept study readouts expected over the next three yearsHighlighting clinical execution... ► Artikel lesen | |
| MODERNA | 31,200 | -4,73 % | Nvidia Rises, Moderna and Brown-Forman Slump, and More | ||
| CYTOKINETICS | 63,11 | -1,67 % | FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS Med | ||
| ARCUTIS BIOTHERAPEUTICS | 28,970 | -1,63 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| EXELIXIS | 46,240 | -0,58 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 145,26 | -1,14 % | Neurocrine: Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced that its Phase 3 KINECT-DCP study evaluating valbenazine in pediatric and adult participants with dyskinetic cerebral palsy... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 784,48 | +0,10 % | Regeneron Pharmaceuticals: Nach erfolgreichem Ausbruch - Pullback-Szenario bietet attraktives Setup! | Chance nach charttechnischem Befreiungsschlag! Rückblick Seit Ende Oktober befindet sich die Regeneron-Aktie in einem stabilen Aufwärtstrend. Nach einem scharfen Rücksetzer hat sich der Kurs über der... ► Artikel lesen | |
| GUARDANT HEALTH | 102,98 | +0,59 % | Guardant Health is the top performing healthcare services stock YTD | ||
| PTC THERAPEUTICS | 78,56 | +0,24 % | PTC Therapeutics erhält Zulassung für PKU-Medikament Sephience in Japan | ||
| PROTAGONIST THERAPEUTICS | 88,78 | -0,07 % | Protagonist Therapeutics: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen |
Das Unternehmen PELTHOS THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,670 (-2,53 %) liegt der Kurs bei 25,810 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PELTHOS THERAPEUTICS INC finden Sie auf Wallstreet Online.